Tori Allen says she's thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more people are using to treat diabetes or lose weight.

“I literally had to buy everything new from bathing suits to pants to shirts.” Dr. Carroll says ... approved for the treatment of diabetes. Eli Lilly then came up with a second-generation ...

(Even larger is U.S.-based Eli Lilly & Co. the maker of Zepbound and ... Impact Analytics found that sales for smaller-sized women’s shirts increased by 12.1%, based on a survey of New York ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

Thanks to impressive sales growth across multiple therapeutic areas in 2024, Eli ... Lilly’s CEO, David Ricks, credited the move to an overestimation of the pace of growth for Mounjaro and Zepbound.

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America’s health focus across ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.